The demand for new transcatheter technologies to treat mitral and tricuspid valve diseases is growing at a remarkable pace. Originally designed for high-risk patients, these therapies are now being used in lower-risk populations. The STS Structural Heart Symposium: Mastery in Mitral and Tricuspid Valve Therapies is designed to help ensure that cardiothoracic surgeons and other members of the heart team possess the appropriative cognitive and technical skills required to safely and effectively perform transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement, and other newer procedures.
This 2-day, Friday/Saturday Symposium will feature didactic sessions, case-based presentations, and hands-on demonstrations of the latest devices by a distinguished multidisciplinary faculty that include pioneers in the treatment of structural heart disease.
After participating in this educational activity, participants should be able to:
- Discuss the decision-making process for the management of structural heart disease and the heart team approach to delivery of care
- Identify ways to treat severe mitral regurgitation, including novel transcatheter approaches and devices
- Describe the patient selection and techniques for tricuspid valve repair, including novel transcatheter approaches
Watch the video below for program highlights, who should attend, and what to expect.
|STS Member Physician||$975|
|STS Associate & Candidate Member||$575|
|Non-Member Allied Health, Resident and Medical Student||$675|
The Society of Thoracic Surgeons is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Society of Thoracic Surgeons designates this live activity for a maximum of 16.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Ethical MedTech Compliance
The 2019 STS Structural Heart Symposium: Mastery in Mitral Valve and Tricuspid Valve Therapies has been assessed by Ethical MedTech and is COMPLIANT with the MedTech Europe Code of Ethical Business Practice.